Lifecore Biomedical, INC \de\ 8-K filings

Lifecore Biomedical's Board of Directors has approved a cash incentive plan for fiscal year 2025, linking executive bonuses to adjusted EBITDA and business objectives.

Lifecore Biomedical will reduce its workforce by approximately 9% to optimize its cost structure, incurring an estimated $1.0 million in termination costs.

Lifecore Biomedical has entered into cooperation agreements with three major investors, resulting in board changes and a commitment to declassify the board.

Lifecore Biomedical has received a notification from Nasdaq regarding non-compliance with listing rules due to delayed financial filings and the annual shareholder meeting.

Lifecore Biomedical has appointed Paul Josephs as its new President and CEO, effective May 20, 2024, and granted him significant equity awards.

Lifecore Biomedical announced it has secured approximately $8 million in incremental liquidity through lender agreements and is assigning assets of a subsidiary for the benefit of creditors.

Lifecore Biomedical secures a new loan tranche and provides additional information to Nasdaq regarding its potential delisting.

Lifecore Biomedical has secured a $5.5 million prepayment from Alcon for future product purchases and announced the date for its 2023 annual shareholder meeting.

Lifecore Biomedical's executive officers will receive their 2024 annual incentive bonuses in fully vested shares of common stock instead of cash.

Lifecore Biomedical has engaged BDO USA, P.C. as its new independent registered public accounting firm, effective immediately, replacing its previous auditor.

Lifecore Biomedical is at risk of being delisted from the Nasdaq due to continued delays in filing its quarterly financial reports.

Lifecore Biomedical provided a business update, including preliminary financial data, full-year fiscal 2024 guidance, and progress on its development portfolio and capacity expansion.

Lifecore Biomedical has announced that Ernst & Young will not stand for reappointment as their independent auditor, prompting a search for a new firm.

Lifecore Biomedical has appointed Paul Josephs as its new CEO, effective May 20, 2024, following the conclusion of a strategic review and the retirement of current CEO James Hall.

Lifecore Biomedical has filed its restated Annual Report on Form 10-K for fiscal year 2023, including restatements for prior periods and providing supplemental financial information.

Lifecore Biomedical has received a delisting notice from Nasdaq due to the late filing of its annual and quarterly financial reports, and intends to appeal the decision.

Lifecore Biomedical has received a notification from Nasdaq regarding non-compliance with listing rules due to delays in filing its financial reports.